Browsing Centre for Evaluation and Methods by Author "Nargesi, S"
Now showing items 1-1 of 1
-
Cost-effectiveness of osimertinib in the treatment of advanced EGFR-mutated non-small cell lung cancer: a systematic review.
Nargesi, S; Dolatshahi, Z; Rezapour, A; Alipour, V; Souresrafil, A; Farabi, H; Javadmoosavi, SA; Safakhah, M; Moradi, N (Taylor & Francis, 2021-12-12)BACKGROUND: The most common type of lung cancer is advanced and mutant non-small cell lung cancer (NSCLC). Although targeted tyrosine kinase inhibitors (TKIs) have reconstructed the care of these patients, the resistance ...